Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia
AssigneeSepracor Inc.
InventorNancy M. Gray
Life of this patent
Estimating the term…
Abstract
Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin.
Claims8
A method of eliciting an increase in urine flow in a human while avoiding the concomitant liability of hypotensive effects associated with racemic doxazosin, which comprises administering to a human an amount of (+) doxazosin, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer, said amount being sufficient to increase urine flow but insufficient to cause said hypotensive effects.
Dependencies are inferred from the claim text.